Latest Hematology Cancer Research to Be Unveiled at 2025 ASH Annual Meeting & Exposition
At the 67th ASH Meeting & Exposition, Dec. 6-9, 2025, in Orlando, City of Hope® will participate in more than 125, including a plenary, oral and poster presentations, scientific symposia and educational sessions. Our experts will share the latest research and clinical innovations shaping care for patients with blood cancers and related disorders, including new therapies and ongoing clinical trials.
Visit us at booth No. 1573 to connect with City of Hope leaders who are redefining cancer care through innovations in bone marrow and stem cell transplants, CAR T cell therapies and microbiome research. Learn more about our Hematopoietic Cell Transplantation and Cellular Therapy Fellowship Programs and how we’re shaping the next generation of specialists in hematologic care.
Home to one of the nation’s largest and most successful bone marrow transplant and cellular therapy programs, City of Hope continues to translate discoveries into improved outcomes for patients.
You're Invited to the City of Hope Networking Reception
Descend 21 | Hyatt Regency Orlando
9801 International Drive, Orlando, FL 32819
Hors d'oeuvres and drinks will be served.
Official meeting badge must be worn for admittance.
R.S.V.P. by Dec. 1, 2025
Hosted By
Marcel van den Brink, M.D., Ph.D.
Marcel van den Brink, M.D., Ph.D., is the president of City of Hope Cancer Center, main campus in Los Angeles, National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair.
Meet and Greet with our Renowned Experts
Saturday, Dec. 6 | 2:30 to 3 p.m. ET
Robert R. Jenq, M.D., is a Professor & Director of the City of Hope Microbiome Program, Department of Hematology and Hematopoietic Cell Transplantation.
Scott James, M.D., Ph.D., is an Assistant Clinical Professor, Division of Leukemia, in the Department of Hematology and Hematopoietic Cell Transplantation.
Sunday, Dec. 7 | 11 to 11:30 a.m. ET
Elizabeth Budde, M.D., Ph.D., is an oncologist and associate professor at City of Hope.
Ryotaro Nakamura, M.D., is the Jan & Mace Siegel Professor in Hematology & Hematopoietic Cell Transplantation professor and a hematologist/oncologist at City of Hope.
Dr. Rodriguez has over 20 years of experience treating blood cancer and is an expert in bone marrow transplantation. He has performed over 2,500 transplant procedures.
Karamjeet Sandhu, M.D., is a hematologist oncologist at City of Hope Cancer Center near Los Angeles, CA.
Highlighted Presentations and Awards
Congratulations to Our Researchers!
Jenny Paredes, Ph.D.
Recipient of the 2025 ASH Abstract Achievement Award
Haris Ali, M.D., FACP, Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Recipient of the Incyte MPN Heroes® Award
Oral Abstract Sessions
Leukemia
Senior Author: Ibrahim Aldoss, M.D., City of Hope associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Plenary 6: Results from paradigm — a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
Sunday, Dec. 7, 3:45 p.m. ET
Also presented by Dr. Aldoss:
443: CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD-remission
Sunday, Dec. 7, 10:30 a.m. ET
Lymphoma
Presented by Alex Herrera, M.D., City of Hope professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
151: Three-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma
Saturday, Dec. 6, noon ET
Presented by Elizabeth Budde, M.D., Ph.D., City of Hope associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
268: BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease
Saturday, Dec. 6, 2:45 p.m. ET
Presented by Tycel Phillips, M.D., associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
883: Interim analysis of the phase II study of glofitamab, lenalidomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. Response and safety outcomes after the completion of stage 1 of 2 enrollment.
Monday, Dec. 8 at 2:45 p.m. ET
Presented by Lindsey Murphy, M.D., M.S., City of Hope assistant professor, Department of Pediatrics
1013: CAR T cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma
Monday, Dec. 8, 5:30 p.m. ET
Myeloma
Presented by Azra Borogovac, M.D., M.S., City of Hope assistant professor, Department of Hematology & Hematopoietic Cell Transplantation
405: Safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (RRMM)
Saturday, Dec. 6, 4:30 p.m. ET
Transplantation
Presented by Monzr M. Al Malki, M.D., City of Hope professor, Department of Hematology & Hematopoietic Cell Transplantation
376: Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with relapsed/refractory (R/R) disease
Saturday, Dec. 6, 4:45 p.m. ET
Presented by Amandeep Salhotra, M.D., City of Hope associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
276: First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation
Saturday, Dec. 6, 3:15 p.m. ET
Presented by Andri Lemarquis, M.D., Ph.D., City of Hope staff scientist
160: A TLR4-HSP70 efferocytic program in thymic macrophages sustains thymic homeostasis and T cell output
Saturday, Dec. 6, 12:45 p.m. ET
City of Hope-Led Educational Sessions
Co-chair: Marcel van den Brink, M.D., Ph.D., City of Hope chief physician executive
14th Annual BMT & Cell Therapy Winter Workshop
Friday, Dec. 5, 1:30-8 p.m. ET
Register for virtual attendance here.
Also presented by Dr. van den Brink:
Scientific Workshop: Microbiome and Diet and Cancer Immunotherapy
Friday, Dec. 5, 3:06 p.m. ET
Presented by Ibrahim Aldoss, M.D., City of Hope associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Satellite Symposia fss25-93: Moving Forward in B-ALL: Insights on Modern and Emerging Standards with Off-the-Shelf Bispecific Antibodies
Friday, Dec. 5, 7 a.m. ET
Chair: Pamela Becker, M.D., Ph.D., professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Scientific Workshop on State of the Art (ws25-58): Integrating Functional and Genomic Precision Medicine for Hematologic Malignancies
Friday, Dec. 5, 3 p.m. ET
Presented by Alex Herrera, M.D., City of Hope professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
How I Treat: How I Incorporate Novel Therapies into Hodgkin Lymphoma Treatment: Frontline vs. Relapse
Sunday, Dec. 7 at 8 a.m. ET
Presented by Randy Taplitz, M.D., City of Hope professor, Department of Medicine
Educational Spotlight: Measures to Minimize Infection Risk in Immunocompromised Patients after Cellular Therapies — How, for Whom, for How Long?
Monday, Dec. 8, 4:30 p.m. ET
14th Annual Bone Marrow Transplant and Cell Therapy Winter Workshop
Dec. 5, 2025, 1:30 pm ET
Hyatt Regency Orlando International Airport
9300 Jeff Fuqua Boulevard., Orlando, FL 32827
Resources
City of Hope is the largest and most successful bone marrow and blood stem cell transplant program in the nation, with over 20,000 bone marrow transplant procedures performed to date — both autologous and allogeneic — through our cancer centers in Duarte, California, Phoenix, Chicago and Atlanta.
Our dedicated, multidisciplinary team of health care and research professionals combine innovative research discoveries with superior clinical treatments to improve outcomes for patients with hematologic cancers.
As a pioneer in advancing care for all hematologic cancers and related blood disorders, City of Hope's Department of Hematology & Hematopoietic Cell Transplantation leads the field as one of the largest and most successful transplant centers in the U.S.
One of the most promising areas of cancer research and treatment is known as immunotherapy, in which a patient’s own immune system is enlisted in the fight against cancer. This approach is more than just a narrow field of study at City of Hope. It is the central component of groundbreaking research and clinical trials currently underway.
In the global pursuit of scientific miracles in the fight against deadly diseases, the Beckman Research Institute of City of Hope is among those leading the charge. Its world-renowned staff have been responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
We’re aggressively pursuing ways to help our patients right now — not years from now. That immediacy of focus makes City of Hope a worldwide leader in administering clinical trials. Each year, we conduct more than 730 clinical trials enrolling more than 5,000 patients.
We are a leader in clinical and translational research, most notably in antibody-based therapy, CAR T cell therapy and bone marrow transplant approaches. When you refer your patient to City of Hope, you can do so with the utmost confidence that our staff will provide the best care possible for your patient.
We’re looking for extraordinary individuals to join our internationally renowned community of physicians, researchers and other health care professionals.
Hosted by Sumanta (Monty) Pal, M.D., F.A.S.C.O., co-director of the Kidney Cancer Program on the Duarte campus, the podcast, "On the Edge of Breakthrough: Voices of Cancer Research" features world-leading oncology experts who explore the latest scientific research and clinical innovations shaping the future of cancer treatment and care.
